Author

Xiaotong Hu

Observed names: Hu, Xiaotong, X. Hu

Institution: Jiangsu Hengrui Medicine (China)

Observed institutions: Amgen (United States), Jiangsu Hengrui Medicine (China)

ORCID: 0009-0004-7958-4869

Observed ORCID: 0009-0004-7958-4869

OpenAlex ID: A5087783340

Ab0432 Efavaleukin Alfa, a Novel Il-2 Mutein, Selectively Expands Regulatory T Cells in Patients With Sle: Final Results of a Phase 1b Multiple Ascending Dose Study

2022 · N. Tchao, N. Sarkar, et al. · Annals of the Rheumatic Diseases · 13

Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of SHR4640, a Selective Human Urate Transporter 1 Inhibitor

2024 · Xiaotong Hu, Hongda Lin, et al. · The Journal of Clinical Pharmacology · 3

Evaluating the drug-drug interactions of SHR4640 on repaglinide and midazolam in healthy subjects

2024 · Yuanzhi Cheng, Xiaotong Hu, et al. · Expert Opinion on Drug Metabolism & Toxicology · 2

Op0140 Regulatory T Cell Defects in Sle and Therapy With a Novel Il-2 Mutein: Phase 1 Clinical Results With Efavaleukin Alfa

2023 · N. Sarkar, X. Hu, et al. · Annals of the Rheumatic Diseases · 2

Characterization of a Long-Acting Anti-Human MASP-2 Antibody for the Treatment of Complement-Related Diseases

2025 · Xiangli Han, Changyong Yang, et al. · Journal of Inflammation Research · 1

Safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-2010, a novel anti-MASP-2 antibody, in healthy volunteers: a randomized, double-blind, placebo-controlled phase 1 study

2025 · Pingping Lin, Chenjing Wang, et al. · Expert Opinion on Investigational Drugs · 1

Works count: 8

Citation count: 22

H-index: 2

I10-index: 1